



02.21-07

IFCN
\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|-------------|----------------------------------|---|-----------------|------------|
| Applicant: | Kristof Chwalisz |) | Examiner: | N.R. Handy |
| | |) | | |
| Serial No.: | 10/807,942 |) | Group Art Unit: | 1616 |
| | |) | | |
| Filed: | 03/24/2004 |) | | |
| | |) | | |
| For: | Use of Sequential SPRM/Progestin |) | | |
| | Treatment |) | | |


INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Entry into the record is respectfully requested. Please charge the \$180.00 fee for filing this Information Disclosure Statement deposit account number: 04-2223.

Respectfully submitted

By 
Lisa V. Mueller, Reg. No. 38,978

Dykema Gossett PLLC
10 South Wacker Drive, Suite 2300
Chicago, Illinois 60606 USA
(312)-876-1700
(312)-876-2302 (Facsimile)

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service via Express Mail EV 892825649 in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on **February 20, 2007**.

02/22/2007 AAD0F01 00000001 042223 10007942



01 FC:1006

180.00 DA





ABB1259P00381US

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|---|----------------------|------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/807,942 |
| | | | | Filing Date | 03/24/04 |
| | | | | First Named Inventor | Kristof Chwalisz |
| | | | | Group Art Unit | 1616 |
| | | | | Examiner Name | N.R. Handy |
| Sheet | 2 | of | 3 | Attorney Docket No. | ABB1259P00381US |

FOREIGN PATENT DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------------------|--------------------------|---|--------------------------------|--|--|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | | WO 99/45023 | 09-10-1999 | Jenapharm et al. | | |
| | | EP0909764 | 04-21-1999 | Jenapharm GmbH | | |
| | | WO 01/15679 | 03-08-2001 | Schering AG et al. | | |
| | | WO 01/26603 | 04-19-2001 | Schering AG et al. | | |
| | | WO 01/34126 | 05-17-2001 | Jenapharm et al. | | |
| | | WO 01/90137 | 11-29-2001 | Jenapharm et al. | | |
| | | WO 02/38581 | 05-16-2002 | Jenapharm et al. | | |
| | | WO 02/38582 | 05-16-2002 | Jenapharm et al. | | |
| | | WO 02/38583 | 05-16-2002 | Jenapharm et al. | | |
| | | WO 03/090786 | 11-16-2003 | Jenapharm et al. | | |
| | | WO 03/090714 | 11-06-2003 | Jenapharm et al. | | |
| | | WO 03/090721 | 11-06-2003 | Jenapharm et al. | | |
| | | WO 03/091272 | 11-06-2003 | Jenapharm et al. | | |
| | | WO 2004/045620 | 06-03-2004 | TAP Pharmaceutical Products Inc. | | |
| Examiner Signature | | | | | Date Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|---|----------------------|------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/807,942 |
| | | | | Filing Date | 03/24/04 |
| | | | | First Named Inventor | Kristof Chwalisz |
| | | | | Group Art Unit | 1616 |
| | | | | Examiner Name | N.R. Handy |
| Sheet | 3 | of | 3 | Attorney Docket No. | ABB1259P00381US |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|--------------------------|---|-----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Demanno D et al., "Asoprisnil (J867): A Selective Progesterone Receptor Modulator for Gynecological Therapy," <i>Steroids</i> , 68(10-13):1019-1032 (November 2003). | |
| | | Chwalisz K et al., "Antiproliferative Effects of Progesterone Antagonists and Progesterone Receptor Modulators on the Endometrium", <i>Steroids</i> , 65(10-11): 741-751 (October 2000). | |
| | | Written Opinion mailed 10/18/2006 for PCT/US2005/009317 | |
| | | Search Report mailed 10/18/2006 for PCT/US2005/009317 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Examiner Signature | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.